Monoclonal Antibodies (mAbs) Market Trends ,Industry Overview And Forecast From 2018 To 2024| Grand View Research, Inc
“The global monoclonal antibodies (mAbs) market accounted for USD 85.4 billion in 2015 and is expected to exhibit a growth rate of 5.7% over the forecast period.�
Global Monoclonal Antibodies (mAbs) Market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies market growth over the forecast period. Increasing demand for personalized medicine is a vital factor responsible for the increasing development of therapeutic antibodies to provide targeted therapies as every individual responds in a different manner to a particular treatment. Moreover, related benefits of using mAbs for therapeutic purposes, including fewer adverse effects, homogeneity, specificity, and large-scale production, are contributing toward significant market growth. In addition, the government initiatives to enable cost-effective production of mAbs is anticipated to propel the emergence of this sector over the forecast period. For instance, the biomanufacturing initiative byNational Institute of Standards and Technology in the U.S. provides scientifically sound regulatory guidelines to ensure effective and safe manufacturing of protein therapeutics and to support biopharmaceutical manufacturers in offering low-cost and high-quality protein drugs across the globe.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
Follow Us:
Further key findings from the study suggest:
Human-based mAbs segment is predicted to grow at a lucrative CAGR in the coming years due to their associated benefits and numerous R&D activities conducted for further development of human mAbs. Large number of mAbs of human origin are in phase III clinical trial for cancer treatment
In vitro production of mAbs is anticipated to show the fastest growth owing to its wide-scale adoption by biologics manufacturers due to its greater efficiency in cost and time
The research institute segment is anticipated to exhibit profitable growth due to increasing R&D efforts in the biotech industry as monoclonal antibodies have emerged as a major class of therapeutics for several human diseases, particularly immunological infectious diseases and cancer
The Asia pacific region has significant growth potential due to rising government initiatives in this region supporting the use of mAbs for research and treatment purposes coupled with the surge in sponsored R&D projects for the development of cost-effective therapeutic mAbs.
For instance, government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct mAb research and development.
The key players serving the monoclonal antibodies market arePfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc, Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers Squibb Co.,Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk A/S.
The introduction of advanced methods for mAb production further encourages the pharmaceutical companies to build their own product pipeline. According to a study published by NCBI at the end of 2013, approximately 816 companies were involved in therapeutic protein research.
Grand View Research has segmented the monoclonal antibodies market by source type, production, indication, enduse, and region: Global Monoclonal Antibodies Source Type Outlook (Revenue, USD Billion, 2013 - 2024) Murine
Chimeric
Humanized
Human
Global Monoclonal Antibodies Production Type Outlook (Revenue, USD Billion, 2013 - 2024) In Vivo
In Vitro
Global Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 - 2024) Cancer
Autoimmune Diseases
Inflammatory Diseases
Follow Us:
Infectious Diseases
Microbial Diseases
Others
Global Monoclonal Antibodies End-use Outlook (Revenue, USD Billion, 2013 - 2024) Hospitals
Research Institutes
Others
Monoclonal antibodies Market Regional Outlook (Market Revenue in USD Billion, 2013 - 2024) North America
o
U.S.
o
Canada
Europe o
UK
o
Germany
Asia Pacific o
Japan
o
China
o
India
Latin America o
Brazil
o
Mexico
Middle East and Africa o
South Africa
Browse Related Category Reports @ https://www.grandviewresearch.com/industry/biotechnology Table of Content of Biological Implants Market Chapter 1 Research Methodology & Scope 1.1 Region Wise Market Calculation 1.1.1 Region Wise Market: Base Estimates 1.1.2 Global Market: CAGR Calculation 1.2 Region based segment share calculation
Follow Us:
1.3 List of Secondary Sources Chapter 2 Executive Summary Chapter 3 Market Snapshot Chapter 4 Market Variables, Trends & Scope 4.1 Market segmentation & scope 4.1.1 Market Driver Analysis 4.1.1.1 Increasing incidences of chronic diseases 4.1.1.2 Technological advancements 4.1.1.3 Growing awareness levels 4.2 Market Restraint Analysis 4.2.1.1 High cost of therapeutic mAbs 4.3 Penetration & growth prospect mapping 4.4 Monoclonal Antibodies - SWOT Analysis, By Factor (political & legal, economic and technological) 4.5 Industry Analysis - Porter’s Chapter 5 Market Categorization 1: Source Type Estimates & Trend Analysis 5.1 Monoclonal antibodies market: Source type movement analysis 5.2 Murine 5.2.1 Murine market, 2013 - 2024 (USD Billion) 5.3 Chimeric 5.3.1 Chimeric market, 2013 - 2024 (USD Billion) 5.4 Humanized 5.4.1 Humanized market, 2013 - 2024 (USD Billion) 5.5 Human 5.5.1.1 Human market, 2013 - 2024 (USD Billion) Chapter 6 Market Categorization 2: Production Type Estimates & Trend Analysis 6.1 Monoclonal antibodies market: Production type movement analysis 6.2 In vitro 6.2.1 In vitro market, 2013 - 2024 (USD Billion) 6.3 In vivo 6.3.1 In vivo market, 2013 - 2024 (USD Billion) Chapter 7 Market Categorization 3: Indication Estimates & Trend Analysis 7.1 Monoclonal antibodies market: Disease movement analysis
Follow Us:
7.2 Cancer 7.2.1 Cancer Market, 2013 - 2024 (USD Billion) 7.3 Autoimmune diseases 7.3.1 Autoimmune diseases market, 2013 - 2024 (USD Billion) 7.4 Inflammatory diseases 7.4.1 Inflammatory diseases market, 2013 - 2024 (USD Billion) 7.5 Infectious diseases 7.5.1 Infectious diseases market, 2013 - 2024 (USD Billion) 7.6 Microbial diseases 7.6.1 Microbial diseases market, 2013 - 2024 (USD Billion) 7.7 Others 7.7.1 Others diseases market, 2013 - 2024 (USD Billion) Chapter 8 Market Categorization 4: End-Use Estimates & Trend Analysis 8.1 Monoclonal antibodies market: End-use movement analysis 8.2 Hospitals 8.2.1 Hospitals market, 2013 - 2024 (USD Billion) 8.3 Research Institutes 8.3.1 Research institutes market, 2013 - 2024 (USD Billion) 8.4 Others 8.4.1 Others market, 2013 - 2024 (USD Billion) Chapter 9 Market Categorization 5: Regional Estimates & Trend Analysis, by Source Type, Production Type, Indication & End-Use 9.1 Monoclonal antibodies market shares by region, 2015 & 2024 9.2 North America 9.2.1 North America Monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.2.2 U.S. 9.2.2.1 U.S. monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.2.3 Canada 9.2.3.1 Canada monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.3 Europe 9.3.1.1 Europe monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.3.2 Germany
Follow Us:
9.3.2.1 Germany monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.3.3 UK 9.3.3.1 UK monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.4 Asia Pacific 9.4.1.1 Asia Pacific monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.4.2 Japan 9.4.2.1 Japan monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.4.3 China 9.4.3.1 China monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.4.4 India 9.4.4.1 India monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.5 Latin America 9.5.1.1 Latin America monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.5.2 Brazil 9.5.2.1 Brazil monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.5.3 Mexico 9.5.3.1 Mexico monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.6 MEA 9.6.1.1 MEA monoclonal antibodies market estimates and forecasts, 2013 - 2024 9.6.2 South Africa 9.6.2.1 South Africa Monoclonal antibodies market estimates and forecasts, 2013 - 2024 Chapter 10 Competitive Landscape 10.1 Strategy framework 10.2 Market participation categorization 10.3 Company Profiles 10.3.1 Novartis International 10.3.1.1 Company Overview 10.3.1.2 Financial Performance 10.3.1.3 Product Benchmarking 10.3.1.4 Strategic Initiatives 10.3.2 Pfizer 10.3.2.1 Company Overview
Follow Us:
10.3.2.2 Financial Performance 10.3.2.3 Product Benchmarking 10.3.2.4 Strategic Initiatives 10.3.3 GlaxoSmithKline Plc 10.3.3.1 Company Overview 10.3.3.2 Financial Performance 10.3.3.3 Product Benchmarking 10.3.3.4 Strategic Initiatives 10.3.4 Amgen Inc. 10.3.4.1 Company Overview 10.3.4.2 Financial Performance 10.3.4.3 Product Benchmarking 10.3.4.4 Strategic Initiatives 10.3.5 Merck & Co., Inc. 10.3.5.1 Company Overview 10.3.5.2 Financial Performance 10.3.5.3 Product Benchmarking 10.3.5.4 Strategic Initiatives 10.3.6 Daiichi Sankyo 10.3.6.1 Company Overview 10.3.6.2 Financial Performance 10.3.6.3 Product Benchmarking 10.3.6.4 Strategic Initiatives 10.3.7 Abbott Laboratories 10.3.7.1 Company Overview 10.3.7.2 Financial Performance 10.3.7.3 Product Benchmarking 10.3.7.4 Strategic Initiatives 10.3.8 AstraZeneca plc 10.3.8.1 Company Overview 10.3.8.2 Financial Performance 10.3.8.3 Product Benchmarking
Follow Us:
10.3.8.4 Strategic Initiatives 10.3.9 Eli Lilly 10.3.9.1 Company Overview 10.3.9.2 Financial Performance 10.3.9.3 Product Benchmarking 10.3.9.4 Strategic Initiatives 10.3.10 Johnson & Johnson 10.3.10.1 Company Overview 10.3.10.2 Financial Performance 10.3.10.3 Product Benchmarking 10.3.10.4 Strategic Initiatives 10.3.11 Bayer AG 10.3.11.1 Company Overview 10.3.11.2 Financial Performance 10.3.11.3 Product Benchmarking 10.3.11.4 Strategic Initiatives 10.3.12 Bristol Myers Squibb 10.3.12.1 Company Overview 10.3.12.2 Financial Performance 10.3.12.3 Product Benchmarking 10.3.12.4 Strategic Initiatives 10.3.13 F.Hoffman-La Roche Ltd. 10.3.13.1 Company Overview 10.3.13.2 Financial Performance 10.3.13.3 Product Benchmarking 10.3.13.4 Strategic Initiatives 10.3.14 Mylan N.V. 10.3.14.1 Company Overview 10.3.14.2 Financial Performance 10.3.14.3 Product Benchmarking 10.3.14.4 Strategic Initiatives 10.3.15 Biogen Idec Inc.
Follow Us:
10.3.15.1 Company Overview 10.3.15.2 Financial Performance 10.3.15.3 Product Benchmarking 10.3.15.4 Strategic Initiatives 10.3.16 Thermo Fisher Scientific 10.3.16.1 Company Overview 10.3.16.2 Financial Performance 10.3.16.3 Product Benchmarking 10.3.16.4 Strategic Initiatives 10.3.17 Novo Nordisk 10.3.17.1 Company Overview 10.3.17.2 Financial Performance 10.3.17.3 Product Benchmarking 10.3.17.4 Strategic Initiatives 10.3.18 Sanofi 10.3.18.1 Company Overview 10.3.18.2 Financial Performance 10.3.18.3 Product Benchmarking 10.3.18.4 Strategic Initiatives 10.3.19 Genzyme 10.3.19.1 Company Overview 10.3.19.2 Financial Performance 10.3.19.3 Product Benchmarking 10.3.19.4 Strategic Initiatives
Follow Us:
About Us: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com
Follow Us: